MedTrace Logo

Synbiotic Compound to Reduce Symptoms of Schizophrenia

NCT04226898 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2026-04-07

No results posted yet for this study

Summary

The purpose of this study is to determine if taking a synbiotic supplement versus a placebo will reduce symptoms of schizophrenia when used in addition to standard antipsychotic medications.

Conditions

Interventions

BIOLOGICAL

Synbiotic Supplement

Synbiotic supplement 1 powder stick by mouth daily

BIOLOGICAL

Inert Compound

Synbiotic supplement identical placebo 1 powder stick by mouth daily

Sponsors & Collaborators

  • Sheppard Pratt Health System

    lead OTHER

Principal Investigators

  • Faith Dickerson, PhD, MPH · Sheppard Pratt Health System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-21
Primary Completion
2027-03-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04226898 on ClinicalTrials.gov